Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.

Slides:



Advertisements
Similar presentations
Bioequivalence Studies Anoop Agarwal
Advertisements

III. Drug Metabolism  The aim of drug metabolism is to convert lipid soluble (non polar) drugs to polar metabolites easily excreted in urine.  The liver.
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence.
Pharmaceutics I Introduction 1. Pharmaceutics Pharmaceutics is the science of dosage form design. There are many chemicals with known pharmacological.
Dale P. Conner, Pharm.D. Division of Bioequivalence OGD, CDER, FDA
Bioavailability and Bioequivalence
Hanoi, WORKSHOP ON PREQUALIFICATION OF ARV: BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence Study Design and Conduct Presented.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
AND GENERIC DRUGS BRAND-NAME AND GENERIC DRUGS WHAT TO CHOOSE? Natalia VEZIKOVA, MD, PhD, Natalia VEZIKOVA, MD, PhD, MSc The Head of the Hospital Therapy.
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Bioequivalence of Topical Drug Products
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Bioequivalence Studies Dr Sanet Aspinall, PhD Managing Director AddClin Research Pretoria 20 March 2009.
Gokaraju Rangaraju College of Pharmacy
ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering Universiti Malaysia Perlis.
ERT 420 BIOPHARMACEUTICAL ENGINEERING ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering.
OVERVIEW OF DACA BIOEQUIVALENCE REPORT EVALUATION Presented by Solomon Shiferaw 31Augst 2010.
Week 6- Bioavailability and Bioequivalence
PHARMACOKINETICS 1. Fate of drugs in the body 1.1 absorption
ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
Bioavailability  The in- vitro methods of evaluating dosage forms provide only indirect evidence of the therapeutic utility of the drug in a given dosage.
Bioavailability Dr Mohammad Issa.
Issues in Generic Substitution: Safety/Efficacy, Cost Savings and Supply Robert J. Herman, MD, FRCPC Professor, Department of Medicine University of Calgary.
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Center for Professional Advancement Generic Drug Approvals Course Bioequivalence & Bioavailability Michael A. Swit, Esq. Vice President.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
Bioequivalence Dr Mohammad Issa Saleh.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
Grade Statistics without Bonus with Bonus Average = 86 Median = 87 Average = 88 Median = 89 Undergraduates Average=88 MS Average=92.
COMPETITION Dr. Muslim Suardi, MSi., Apt. School of Pharmacy, Faculty of Sciences University of Andalas.
INTRODUCTION CLINICAL PHARMACOKINETICS
Bioavailability and Bioequivalence General concepts and overview
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Bioavailability and Bioequivalence L 10,11.  Bioavailability is a measurement of the rate and extent (amount) to which the active ingredient or active.
Dr. Muslim Suardi, MSi., Apt. School of Pharmacy, Faculty of Sciences University of Andalas.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy, University of Andalas.
Design of Sustained Release Dosage Forms
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
415 PHT Plasma Level – Time Curve
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Definitions and Concepts
Rates & Orders of Reactions Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
Drug Response Relationships
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Pharmacology I BMS 242 Lecture II (Continued)
Prof. Dr. Basavaraj K. Nanjwade
Prof. Dr. Basavaraj K. Nanjwade M. Pharm., PhD
Generic Medicines.
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
INTRODUCTION The oral route of drugs administration is the most important method of administering drugs for systemic effects.
The percentage of NASs approved by CDER
Pharmacology I BMS 242 Lecture II (Continued)
Median 25th and 75th percentile
Conference Series LLC Conferences
Percentage Key Message
Clinical Pharmacokinetics
INTRODUCTION to Pharmacology
Pharmaceutics I Introduction 1. Pharmaceutics Pharmaceutics is the science of dosage form design. There are many chemicals with known pharmacological.
Bioequivalence trials: design, evaluation, regulatory requirements
Median times to submission and licensing for 70 new active substances approved in five markets from 1997 to 2010 Note: EMA approval.
GL8 (R) – Stability testing for medicated premixes
Presentation transcript:

Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas

“The rate & extent to which the active substance or active moiety is absorbed from a pharmaceutical form & becomes available at the site of action”.

Absolute BA Compared with that (100%) following iv administration (e.g. oral solution vs. iv.). Relative BA Compared with another form administered by the same or another non iv route (e.g. tablets vs. oral solution).

“Two medicinal products are BE if they are their BA after administration in the same molar dose are similar to such degree that their effects, with respect to both efficacy & safety, will be essentially the same”.

A medicinal product authorized & marketed on the basis of a full dossier i.e. including chemical, biological, pharmaceutical, pharmacological-toxicological & clinical data.

Contains the same active substance or therapeutic moiety and, clinically, shows the same efficacy and safety as that product, whose efficacy & safety has been established.

AUC C max t max  Additional information, k a t ½ & MRT  AUCt is the most reliable reflection of the extent of absorption.  AUCt C max, C min & fluctuation.